“Impact of Drug Crystallinity on Pharmacokinetics in Tacrolimus Formulations”

Dr Tomasz Turek

“Impact of Drug Crystallinity on Pharmacokinetics in Tacrolimus Formulations”

Authors: Dr Tomasz Turek

Published: 2025-03-06 12:21:40.363

Abstract

Tacrolimus, an immunosuppressive drug with a narrow therapeutic index, exhibits significant pharmacokinetic variability influenced by its crystallinity. This study investigates the impact of drug crystallinity on key pharmacokinetic parameters, including maximum concentration (Cmax) and area under the curve (AUC), through a randomized, single-dose, four-treatment, four-period, four-way crossover study. Findings demonstrate that increased crystallinity leads to higher Cmax and lower AUC, presenting challenges in achieving bioequivalence with reference listed drugs (RLD). The study further explores the mechanistic underpinnings, indicating that solubility and dissolution rate modifications mediate these pharmacokinetic changes. Clinical implications suggest that crystallinity variability necessitates tailored formulation strategies to ensure therapeutic efficacy and consistent drug exposure. The results emphasize the need for stringent crystallinity control in tacrolimus formulations to optimize pharmacokinetic performance and improve clinical outcomes.

Keywords

Tacrolimus, drug crystallinity, pharmacokinetics, bioequivalence, solubility, dissolution rate, drug formulation, maximum concentration (Cmax), area under the curve (AUC), therapeutic efficacy

References

Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3), 413–420.
Basit, A. W., & Hussain, M. (2020). The influence of drug crystallinity on oral bioavailability: A review. Journal of Pharmaceutical Sciences, 109(5), 1417–1428.
Chen, L., Zhu, L., Xu, P., & Zhang, X. (2021). The role of drug crystallinity in determining pharmacokinetic behavior: Implications for formulation development. International Journal of Pharmaceutics, 601, 120590.
European Medicines Agency (EMA). (2018). Guideline on the pharmacokinetic and clinical evaluation of modified-release dosage forms. EMA/CHMP/EWP/280/96 Rev1.
Gandhi, S. V., Gilbert, S. B., & Zhou, J. (2019). Challenges in achieving bioequivalence for poorly soluble drugs: Case study of tacrolimus. Journal of Pharmaceutical and Biomedical Analysis, 164, 195–204.
Kesisoglou, F., & Mitra, A. (2020). Impact of amorphous drug formulations on pharmacokinetics: Case studies and formulation considerations. AAPS Journal, 22(3), 45.
Kim, S., Kim, J. H., Kim, M. S., & Park, J. S. (2017). Effect of crystallinity on dissolution and bioavailability of tacrolimus: A comparative study. Drug Development and Industrial Pharmacy, 43(7), 1105–1113.
Lennernäs, H., & Aarons, L. (2021). Bioequivalence and variability in drug absorption: The significance of drug formulation. Clinical Pharmacokinetics, 60(5), 573–589.
Shah, V. P., & Skelly, J. P. (2019). Regulatory considerations in the development of bioequivalent tacrolimus formulations. Advances in Drug Delivery Reviews, 151, 132–145.
Wu, Y., Levons, J., Narang, A. S., Raghavan, K., & Rao, V. (2011). Reactive impurities in excipients: Profiling, identification and mitigation of drug-excipient incompatibility. AAPS PharmSciTech, 12(4), 1248–1263.

Download PDF

How to Cite

Dr Tomasz Turek, (2025-03-06 12:21:40.363). “Impact of Drug Crystallinity on Pharmacokinetics in Tacrolimus Formulations”. JANOLI International Journal of Pharmaceuticals and Chemicals, Volume t8VTiGjctuTvNUTp50bc, Issue 1.

ISSN: A/F

JANOLI International Journal of
Pharmaceuticals and Chemicals ( JIJPC )